Cargando…

Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries

Sanwei-Tanxiang powder (SWTX), a traditional Mongolian and Tibetan medicine containing a cocktail of active molecules, relieves angina pectoris and improves recovery in patients with coronary heart disease (CHD). The pharmacological effect of SWTX on CHD was analyzed at a systemic point of view in o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yu-Hui, Bu, Ren, Wang, Yue-Wu, Hu, Yu-Chong, Wang, Xu-Mei, Dong, Xin, Zu, Wen, Niu, Yan, Zhao, Peng-Wei, Sun, Peng, Ru, Shi-Hang, Lu, Jing-Kun, Na, Sheng-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804470/
https://www.ncbi.nlm.nih.gov/pubmed/33437022
http://dx.doi.org/10.1038/s41598-020-80861-6
_version_ 1783636172030869504
author Sun, Yu-Hui
Bu, Ren
Wang, Yue-Wu
Hu, Yu-Chong
Wang, Xu-Mei
Dong, Xin
Zu, Wen
Niu, Yan
Zhao, Peng-Wei
Sun, Peng
Ru, Shi-Hang
Lu, Jing-Kun
Na, Sheng-Sang
author_facet Sun, Yu-Hui
Bu, Ren
Wang, Yue-Wu
Hu, Yu-Chong
Wang, Xu-Mei
Dong, Xin
Zu, Wen
Niu, Yan
Zhao, Peng-Wei
Sun, Peng
Ru, Shi-Hang
Lu, Jing-Kun
Na, Sheng-Sang
author_sort Sun, Yu-Hui
collection PubMed
description Sanwei-Tanxiang powder (SWTX), a traditional Mongolian and Tibetan medicine containing a cocktail of active molecules, relieves angina pectoris and improves recovery in patients with coronary heart disease (CHD). The pharmacological effect of SWTX on CHD was analyzed at a systemic point of view in our previous studies. The bioinformatics prediction showed that the PI3K/Akt/FoxO3a pathway was one of important pathways of SWTX on treatment of coronary heart disease. Based on it, the aim of this study was to evaluate the benefits of SWTX in acute myocardial ischemic-reperfused (MIR) rat in vivo and H9c2 cardiomyoblast cells under oxidative stress induced by H(2)O(2) in vitro, and further investigate the involvement of PI3K/Akt/FoxO3a pathway in these processes. Ex vivo, under physiological conditions, SWTX did not show any modification in the heart rate and contraction amplitude. However, against a MIR injury, SWTX pretreatment provided significant protection, including reduced ST-segment elevation, pathological changes and myocardial infarct size in vivo, meanwhile, some monomers of SWTX showed antioxidant capacity and inhibited cardiomyocytic apoptosis in vitro. The effect was correlated with the activation of the PI3K/Akt/FoxO3a signaling pathway downstream and the regulation of downstream pro-apoptotic Bim of FoxO3a experimental verified by qRT-PCR, Western blot and immunofluorescent assay. In vitro, blocking Akt and p-FoxO3a activation with the PI3K inhibitor LY294002 effectively suppressed the protective effects of several active monomers (including quercetin, macelignan,methyleugenol and Santol) of SWTX against H(2)O(2)-induced injury. Collectively, these results suggest that SWTX decreases I/R injury, and the PI3K/Akt/FoxO3a pathway takes part in protection during this process, gallogen (G3) and quercetin (G8) of GZ, methyleugenol (R2) and macelignan (R7) of RDK, santol (T1) of TX are responsible at least in part for SWTX’s cardioprotection effect.
format Online
Article
Text
id pubmed-7804470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78044702021-01-13 Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries Sun, Yu-Hui Bu, Ren Wang, Yue-Wu Hu, Yu-Chong Wang, Xu-Mei Dong, Xin Zu, Wen Niu, Yan Zhao, Peng-Wei Sun, Peng Ru, Shi-Hang Lu, Jing-Kun Na, Sheng-Sang Sci Rep Article Sanwei-Tanxiang powder (SWTX), a traditional Mongolian and Tibetan medicine containing a cocktail of active molecules, relieves angina pectoris and improves recovery in patients with coronary heart disease (CHD). The pharmacological effect of SWTX on CHD was analyzed at a systemic point of view in our previous studies. The bioinformatics prediction showed that the PI3K/Akt/FoxO3a pathway was one of important pathways of SWTX on treatment of coronary heart disease. Based on it, the aim of this study was to evaluate the benefits of SWTX in acute myocardial ischemic-reperfused (MIR) rat in vivo and H9c2 cardiomyoblast cells under oxidative stress induced by H(2)O(2) in vitro, and further investigate the involvement of PI3K/Akt/FoxO3a pathway in these processes. Ex vivo, under physiological conditions, SWTX did not show any modification in the heart rate and contraction amplitude. However, against a MIR injury, SWTX pretreatment provided significant protection, including reduced ST-segment elevation, pathological changes and myocardial infarct size in vivo, meanwhile, some monomers of SWTX showed antioxidant capacity and inhibited cardiomyocytic apoptosis in vitro. The effect was correlated with the activation of the PI3K/Akt/FoxO3a signaling pathway downstream and the regulation of downstream pro-apoptotic Bim of FoxO3a experimental verified by qRT-PCR, Western blot and immunofluorescent assay. In vitro, blocking Akt and p-FoxO3a activation with the PI3K inhibitor LY294002 effectively suppressed the protective effects of several active monomers (including quercetin, macelignan,methyleugenol and Santol) of SWTX against H(2)O(2)-induced injury. Collectively, these results suggest that SWTX decreases I/R injury, and the PI3K/Akt/FoxO3a pathway takes part in protection during this process, gallogen (G3) and quercetin (G8) of GZ, methyleugenol (R2) and macelignan (R7) of RDK, santol (T1) of TX are responsible at least in part for SWTX’s cardioprotection effect. Nature Publishing Group UK 2021-01-12 /pmc/articles/PMC7804470/ /pubmed/33437022 http://dx.doi.org/10.1038/s41598-020-80861-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Sun, Yu-Hui
Bu, Ren
Wang, Yue-Wu
Hu, Yu-Chong
Wang, Xu-Mei
Dong, Xin
Zu, Wen
Niu, Yan
Zhao, Peng-Wei
Sun, Peng
Ru, Shi-Hang
Lu, Jing-Kun
Na, Sheng-Sang
Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries
title Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries
title_full Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries
title_fullStr Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries
title_full_unstemmed Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries
title_short Validation of efficacy and mechanism of Sanwei-Tanxiang powder in improving myocardial ischemia reperfusion injuries
title_sort validation of efficacy and mechanism of sanwei-tanxiang powder in improving myocardial ischemia reperfusion injuries
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804470/
https://www.ncbi.nlm.nih.gov/pubmed/33437022
http://dx.doi.org/10.1038/s41598-020-80861-6
work_keys_str_mv AT sunyuhui validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT buren validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT wangyuewu validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT huyuchong validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT wangxumei validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT dongxin validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT zuwen validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT niuyan validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT zhaopengwei validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT sunpeng validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT rushihang validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT lujingkun validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries
AT nashengsang validationofefficacyandmechanismofsanweitanxiangpowderinimprovingmyocardialischemiareperfusioninjuries